Email This Article

Headlines & Perspectives
Genentech Investors Monitor Avastin Study
By Elizabeth Trotta
10/15/08 - 03:32 PM EDT
Now that Genentech has a solid quarter under its belt, investors are waiting to see whether a new use for cancer drug Avastin is effective.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,447.85 1,108.66 2,192.17 33.80
Oil *
78.20
DOWN
4.83
DOWN
0.58
UP
7.14
UP
0.57
10 Yr
3.38%
SPDR Gold
119.39
-0.05%
-0.05%
+0.33%
+1.72%
Data delayed 20 minutes

Brokerage Partners